Regencell Bioscience Holdings Limited (RGC) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Causeway Bay, Hong Kong. Der aktuelle CEO ist Yat-Gai Au.
RGC hat IPO-Datum 2021-07-16, 12 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $14.89B.
Regencell Bioscience Holdings Limited is a Traditional Chinese medicine bioscience company incorporated in 2014 and headquartered in Causeway Bay, Hong Kong. The company specializes in the research, development, and commercialization of TCM-based treatments for neurocognitive disorders and degeneration, with a primary focus on attention deficit hyperactivity disorder and autism spectrum disorder. Through its integrated approach to traditional medicine and modern science, Regencell aims to address significant unmet medical needs in neurological health.
